Pablo retweeted
Recordando el ACR 2026 pasado el jet lag, muchos reumatólogos jovenes dejando el liston muy alto y seniors aportando tanto, encantador encuentro con los colegas latinoamericanos, Orgullo de sociedad @SEReumatologia
Pablo retweeted
#IgG4-RD ▶️New guidelines:
Fewer steroids, earlier targeted treatment. Initial prednisone ≤30–40 mg/day; GC monotherapy ≤3 months. Steroid-sparing induction for most; B-cell-directed therapy reduces relapse (1b/A).
Maintenance only in selected patients. thelancet.com/action/showPdf…
Pablo retweeted
Back home, so happy 😃 I could be part of #ACR26 and keen to keep studying and learning Rheumatology. Over the next few days, I’ll catch up on talks I missed and share what I find interesting 🧐
I hope to be at ACR 2027 !!!
Pablo retweeted
📢 Ya disponible la tercera y última entrega de los vídeos resúmenes de #ACReview26, que los revisores/as han ido preparando día a día.
¡Gracias por vuestra gran labor durante este #ACR26! 🙌
Accede aquí a todo el contenido dividido por áreas: ➡️acr-review.ser.es/
Pablo retweeted
IgG4-RD ➡️ Rare, heterogeneous disease (4 phenotypes; male:female 3:1).
Exclude malignancy, infection and inflammatory mimics before diagnosis. Cancer risk remains uncertain.
Limit cumulative GC exposure; consider baseline whole-body imaging case by case. #ACR26
Pablo retweeted
IgG4 Guidelines👇
🔥Hot off the press for #ACR26 🔥
The @IgG4ward foundation guidelines on the treatment of IgG4-related disease
thelancet.com/journals/lanrh…
Free to read on lancet.com
What incredible energy in Orlando! 🌟 Great seeing the EMEUNET community come together at #ACR26 to exchange ideas, discuss priorities, and shape our future. Thanks to everyone who joined!
#eularEMEUNET #Rheumatology #ACR2026 congress
“The IgG4ward! Foundation guidelines on the treatment of IgG4-related disease” are now published in The Lancet Rheumatology. 52 physicians, 10 patients and caregivers, six continents, 28 Statements. Full story and article link at: igg4ward.org/resources/the-i…
#IgG4RD #RareDisease
Pablo retweeted
So happy to present two of our studies at #ACR26 today!
🔹 Abstract 1123: meta-analysis of JAK inhibitors in Takayasu arteritis.
🔹Abstract 1168: systematic review of mepolizumab and benralizumab in EGPA.
Pablo retweeted
Dermatomyositis ▶️ Periungual erythema and cuticular dystrophy may accompany nailfold microangiopathy.
Unpublished study (53 DM vs 41 SLE): capillary dilation 81.1% vs 31.7%, dropout 67.9% vs 24.4%, capillary-bed disruption 77.4% vs 17.1% (all p<0.001). #ACR26
Mil gracias por el apoyo!
#ACR26 Trabajos españoles sobre vasculitis 🙌🙌. No dejéis de pasad a verlos @SEReumatologia
1
6
271
Pablo retweeted
#ACR26 Trabajos españoles sobre vasculitis 🙌🙌. No dejéis de pasad a verlos @SEReumatologia
🎥 Meet José Miguel Sequí-Sabater, one of your #EMEUNET Social Media Correspondents at #ACR26! ✨
Follow @drjsequirheum for congress highlights, key insights and the latest in rheumatology from Orlando. 🇺🇸
📲 Stay tuned !
#eularEMEUNET #ACR26 congress
Pablo retweeted
🦋 Exciting lupus research ahead at #ACR2026!
🦋 What's hot in #LupusResearch at #ACR2026?
🔬 Explore the abstracts selected by Lupus Hub, including our team's ReBioLup study (Abstract 1862)!
🔗 Read more: parodislab.com/2026/11/acr-2…
#Rheumatology













































